FindTrial
Sign In

sFlt-1 / PlGF ratio testing shortens time to diagnosis in patients with suspected preeclampsia: a cluster-randomized controlled trail

sFlt-1 / PlGF ratio testing shortens time to diagnosis in patients with suspected preeclampsia: a cluster-randomized controlled trail

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065702
Enrollment
Unknown
Registered
2022-11-13
Start date
2022-11-15
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia

Interventions

Experimental group:Detection of sFlt-1 / PlGF ratio
Control group:None

Sponsors

Obstetrics and Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Pregnant women suspected of preeclampsia between November 2022 and March 2025, 20+0 to 36+6 weeks of gestation, aged >=18 years, single fetus. Suspected preeclampsia is defined as: new hypertension, progression of pre-existing hypertension, new positive urinary protein, upper or right upper abdominal pain, headache with visual field loss, fetal growth restriction in utero, abnormal laboratory tests (including thrombocytopenia, abnormal liver enzymes, or abnormal kidney function).

Exclusion criteria

Exclusion criteria: 1. Preeclampsia was diagnosed at admission; 2. Those who do not have access to complete follow-up and delivery information; 3. Complicated with other serious diseases.

Design outcomes

Primary

MeasureTime frame
sFlt-1/PlGF ratio;—

Countries

China

Contacts

Public ContactHu Rong

Obstetrics and Gynecology Hospital of Fudan University

hurongwy@sina.com+86 13501911864

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026